Literature DB >> 18045238

EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor fate.

Kathryn A Stern1, Trenton L Place, Nancy L Lill.   

Abstract

EGF-R [EGF (epidermal growth factor) receptor] ligands can promote or inhibit cell growth. The biological outcome of receptor activation is dictated, at least in part, by ligand-specified patterns of endocytic trafficking. EGF-R trafficking downstream of the ligands EGF and TGF-alpha (transforming growth factor-alpha) has been investigated extensively. However, less is known about EGF-R fates induced by the ligands BTC (betacellulin) and AR (amphiregulin). We undertook comparative analyses to identify ligand-specific molecular events that regulate EGF-R trafficking and degradation. EGF (17 nM) and BTC (8.5 nM) induced significant EGF-R degradation, with or without ectopic expression of the ubiquitin ligase Cbl. Human recombinant AR (17 nM) failed to affect receptor degradation in either case. Notably, levels of ligand-induced EGF-R ubiquitination did not correlate strictly with receptor degradation. Dose-response experiments revealed that AR at a saturating concentration was a partial agonist at the EGF-R, with approx. 40% efficacy (relative to EGF) at inducing receptor tyrosine phosphorylation, ubiquitination and association with Cbl. EGF-R down-regulation and degradation also were compromised upon cell stimulation with AR (136 nM). These outcomes correlated with decreased degradation of the Cbl substrate and internalization inhibitor hSprouty2. Downstream of the hSprouty2 checkpoint in AR-stimulated cells, Cbl-free EGF-R was incorporated into endosomes from which Cbl-EGF-R complexes were excluded. Our results suggest that the AR-specific EGF-R fate results from decreased hSprouty2 degradation and reduced Cbl recruitment to underphosphorylated EGF-R, two effects that impair EGF-R trafficking to lysosomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18045238      PMCID: PMC3507514          DOI: 10.1042/BJ20071505

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  50 in total

1.  Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation.

Authors:  Yaron Mosesson; Keren Shtiegman; Menachem Katz; Yaara Zwang; Gyorgi Vereb; Janos Szollosi; Yosef Yarden
Journal:  J Biol Chem       Date:  2003-04-28       Impact factor: 5.157

2.  Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells.

Authors:  Katie L Streicher; Nicole E Willmarth; Jose Garcia; Julie L Boerner; T Gregory Dewey; Stephen P Ethier
Journal:  Mol Cancer Res       Date:  2007-08-01       Impact factor: 5.852

Review 3.  Epidermal growth factor receptor (EGFR) signaling in cancer.

Authors:  Nicola Normanno; Antonella De Luca; Caterina Bianco; Luigi Strizzi; Mario Mancino; Monica R Maiello; Adele Carotenuto; Gianfranco De Feo; Francesco Caponigro; David S Salomon
Journal:  Gene       Date:  2005-12-27       Impact factor: 3.688

4.  Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells.

Authors:  Nicole E Willmarth; Stephen P Ethier
Journal:  J Biol Chem       Date:  2006-10-10       Impact factor: 5.157

5.  Differential effects of amphiregulin and TGF-alpha on the morphology of MDCK cells.

Authors:  Eunkyung Chung; Ramona Graves-Deal; Jeffrey L Franklin; Robert J Coffey
Journal:  Exp Cell Res       Date:  2005-09-10       Impact factor: 3.905

6.  Epidermal growth factor receptor fate is controlled by Hrs tyrosine phosphorylation sites that regulate Hrs degradation.

Authors:  Kathryn A Stern; Gina D Visser Smit; Trenton L Place; Stanley Winistorfer; Robert C Piper; Nancy L Lill
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

7.  hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl.

Authors:  Amy B Hall; Natalia Jura; John DaSilva; Yeon Joo Jang; Delquin Gong; Dafna Bar-Sagi
Journal:  Curr Biol       Date:  2003-02-18       Impact factor: 10.834

8.  Novel role for amphiregulin in protection from liver injury.

Authors:  Carmen Berasain; Elena R García-Trevijano; Josefa Castillo; Elena Erroba; Mónica Santamaría; David C Lee; Jesús Prieto; Matías A Avila
Journal:  J Biol Chem       Date:  2005-03-07       Impact factor: 5.157

9.  Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells.

Authors:  Jennifer L Gilmore; Jeffrey A Scott; Zhor Bouizar; Alex Robling; Sarah E Pitfield; David J Riese; John Foley
Journal:  Breast Cancer Res Treat       Date:  2007-09-20       Impact factor: 4.872

10.  Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation.

Authors:  Kaisa Haglund; Sara Sigismund; Simona Polo; Iwona Szymkiewicz; Pier Paolo Di Fiore; Ivan Dikic
Journal:  Nat Cell Biol       Date:  2003-05       Impact factor: 28.824

View more
  38 in total

1.  Insulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of insulin receptor isoform A.

Authors:  Alaide Morcavallo; Marco Genua; Angela Palummo; Emilia Kletvikova; Jiri Jiracek; Andrzej M Brzozowski; Renato V Iozzo; Antonino Belfiore; Andrea Morrione
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

Review 2.  Effects of membrane trafficking on signaling by receptor tyrosine kinases.

Authors:  Marta Miaczynska
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-11-01       Impact factor: 10.005

3.  Heavy subunit of cell surface Gal/GalNAc lectin (Hgl) undergoes degradation via endo-lysosomal compartments in Entamoeba histolytica.

Authors:  Kuldeep Verma; Sunando Datta
Journal:  Small GTPases       Date:  2017-07-07

4.  Cbl controls EGFR fate by regulating early endosome fusion.

Authors:  Gina D Visser Smit; Trenton L Place; Sara L Cole; Kathryn A Clausen; Soumya Vemuganti; Guojuan Zhang; John G Koland; Nancy L Lill
Journal:  Sci Signal       Date:  2009-12-22       Impact factor: 8.192

5.  β-Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1/2 and Akt.

Authors:  Laurel A Grisanti; Jennifer A Talarico; Rhonda L Carter; Justine E Yu; Ashley A Repas; Scott W Radcliffe; Hoang-Ai Tang; Catherine A Makarewich; Steven R Houser; Douglas G Tilley
Journal:  J Mol Cell Cardiol       Date:  2014-02-22       Impact factor: 5.000

Review 6.  EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling.

Authors:  Kristy J Wilson; Christopher Mill; Sydney Lambert; Jennifer Buchman; Timothy R Wilson; Victor Hernandez-Gordillo; Richard M Gallo; Laura M C Ades; Jeffrey Settleman; David J Riese
Journal:  Growth Factors       Date:  2012-01-20       Impact factor: 2.511

7.  Essential role of c-Cbl in amphiregulin-induced recycling and signaling of the endogenous epidermal growth factor receptor.

Authors:  Aleksander Baldys; Monika Göoz; Thomas A Morinelli; Mi-Hye Lee; John R Raymond; Louis M Luttrell; John R Raymond
Journal:  Biochemistry       Date:  2009-02-24       Impact factor: 3.162

8.  Integrin α6β4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF).

Authors:  Brittany L Carpenter; Min Chen; Teresa Knifley; Kelley A Davis; Susan M W Harrison; Rachel L Stewart; Kathleen L O'Connor
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

9.  An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors.

Authors:  S Carvalho; M Lindzen; M Lauriola; N Shirazi; S Sinha; A Abdul-Hai; K Levanon; J Korach; I Barshack; Y Cohen; A Onn; G Mills; Y Yarden
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

10.  Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Authors:  Magda Bahcall; Mark M Awad; Lynette M Sholl; Frederick H Wilson; Man Xu; Stephen Wang; Sangeetha Palakurthi; Jihyun Choi; Elena V Ivanova; Giulia C Leonardi; Bryan C Ulrich; Cloud P Paweletz; Paul T Kirschmeier; Masayuki Watanabe; Hideo Baba; Mizuki Nishino; Rebecca J Nagy; Richard B Lanman; Marzia Capelletti; Emily S Chambers; Amanda J Redig; Paul A VanderLaan; Daniel B Costa; Yu Imamura; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2018-08-02       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.